Endocrinology and Metabolism

Original Article

Clinical Study
Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation: Jonghwa Ahn, Min Ji Jeon, Eyun Song, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim; Endocrinol Metab. 2020;35(1):115-121. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.115

5,484 View
110 Download
8 Web of Science
12 Crossref

Background

Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation.

Methods

In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire.

Results

The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups.

Conclusion

Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.

Citations

Citations to this article as recorded by

Quality of life of patients with thyroid cancer in Colombia
Oscar Gómez, Alvaro Sanabria
Endocrinología, Diabetes y Nutrición.2024; 71(2): 61. CrossRef
Quality of life of patients with thyroid cancer in Colombia
Oscar Gómez, Alvaro Sanabria
Endocrinología, Diabetes y Nutrición (English ed.).2024; 71(2): 61. CrossRef
Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Jacob Hampton, Ahmad Alam, Nicholas Zdenkowski, Christopher Rowe, Elizabeth Fradgley, Christine J. O'Neill
Thyroid®.2024;[Epub] CrossRef
Review: Improving quality of life in patients with differentiated thyroid cancer
Pia Pace-Asciak, Jonathon O. Russell, Ralph P. Tufano
Frontiers in Oncology.2023;[Epub] CrossRef
Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
Thyroid.2023; 33(4): 474. CrossRef
The "not so good" thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life
Kyle Alexander, Sum-Yu Christina Lee, Stelios Georgiades, Constantina Constantinou
Journal of Medicine and Life.2023; 16(3): 348. CrossRef
Comparison of health‐related quality of life and cosmetic outcome between traditional gasless trans‐axillary endoscopic thyroidectomy and modified gasless trans‐axillary endoscopic thyroidectomy for patients with papillary thyroid microcarcinoma
Deenraj Kush Dhoomun, HuiLan Cai, Ning Li, YanHuan Qiu, XingRui Li, XiaoPeng Hu, WenZhuang Shen
Cancer Medicine.2023; 12(15): 16604. CrossRef
Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
Shinje Moon, Ka Hee Yi, Young Joo Park
Cancers.2022; 14(10): 2382. CrossRef
Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules
Elizabeth J de Koster, Olga Husson, Eveline W C M van Dam, G Sophie Mijnhout, Romana T Netea-Maier, Wim J G Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens, _ _
Endocrine Connections.2022;[Epub] CrossRef
Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment
Poliane A.L. Santos, Maria E.D.M. Flamini, Felipe A. Mourato, Fernando R.A. Lima, Joelan A.L. Santos, Fabiana F. Lima, Estelita T.B. Albuquerque, Alexandra C. De Freitas, Simone C.S. Brandão
Brazilian Journal of Radiation Sciences.2022; 10(4): 1. CrossRef
Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
Surgery.2021; 170(1): 99. CrossRef
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinology and Metabolism.2021; 36(2): 359. CrossRef

Review Article

Thyroid
Graves' Disease: Can It Be Cured?: Wilmar M. Wiersinga; Endocrinol Metab. 2019;34(1):29-38. Published online March 21, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.29

16,153 View
511 Download
44 Web of Science
46 Crossref

Abstract PDF PubReader ePub

Whether or not Graves' hyperthyroidism can be really cured, depends on the definition of “cure.” If eradication of thyroid hormone excess suffices for the label “cure,” then all patients can be cured because total thyroidectomy or high doses of ¹³¹I will abolish hyperthyroidism albeit at the expense of creating another disease (hypothyroidism) requiring lifelong medication with levothyroxine. I would not call this a “cure,” which I would like to define as a state with stable thyroid stimulating hormone (TSH), free thyroxine, and triiodothyronine serum concentrations in the normal range in the absence of any thyroid medication. Surgery and radioiodine are unlikely to result in so-defined cures, as their preferable aim as stated in guidelines is to cause permanent hypothyroidism. Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score. At 20-year follow-up about 62% had developed recurrent hyperthyroidism, 8% had subclinical hypothyroidism, and 3% overt hypothyroidism related to TSH receptor blocking antibodies and thyroid peroxidase antibodies. Only 27% was in remission, and might be considered cured. If the definition of “cure” would also include the disappearance of thyroid antibodies in serum, the proportion of cured patients would become even lower.

Citations

Citations to this article as recorded by

Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, George Frimpong Boafo, Kosheli Thapa Magar, Yanmin Ju, Wei He
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Prenatal double-hit with aluminium and cadmium mediate testicular atrophy and hypothalamic hypoplasia: the role of oxido-nitrergic stress and endocrine perturbations
Emmanuel Okhue, Helen Ejiro Kadiri, Patrick Chukwuyenum Ichipi-Ifukor, Benneth Ben-Azu, Samuel Ogheneovo Asagba, Fidelis Ifeakachuku Achuba, John Chukwuma Oyem
BioMetals.2024; 37(2): 477. CrossRef
Surgical outcome after thyroidectomy due to Graves’ disease and Lugol iodine treatment: a retrospective register-based cohort study
Fredric Hedberg, Henrik Falhammar, Jan Calissendorff, Robert Bränström
Endocrine.2024;[Epub] CrossRef
Graves disease is associated with increased risk of clinical Alzheimer’s disease: evidence from the Medicare system
Arseniy Pavlovich Yashkin, Stanislav Kolpakov, Svetlana Ukraintseva, Anatoliy Yashin, Igor Akushevich
Clinical Diabetes and Endocrinology.2024;[Epub] CrossRef
A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change
Danilo Villagelin, David S Cooper, Henry B Burch
The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves’ Disease: A Pilot Study
Jin-Ying Lu, Kuan-Hua Chen, Shyang-Rong Shih, Fang-Yu Wen, Wan-Chen Wu, Ting-Chu Chen, Fu-Chang Hu
Endocrine Practice.2023; 29(2): 89. CrossRef
Case of Graves’ disease recovery
Andrey Valerievich Ushakov
Journal of Clinical and Translational Endocrinology: Case Reports.2023; 27: 100139. CrossRef
Outcomes of Radioactive Iodine Versus Surgery for the Treatment of Graves’ Disease: a Systematic Review and Meta-analysis
Mohamed AbdAlla Salman, Mohamed Moustafa Assal, Ahmed Salman, Mohammed Elsherbiney
Indian Journal of Surgery.2023;[Epub] CrossRef
Association between high mobility group box-1 circulation level and Graves' ophthalmopathy
Mohammad Robikhul Ikhsan, Nyoman Kertia, Supanji Supanji, Bambang Udji djoko Rianto, Dhite Bayu Nugroho
F1000Research.2023; 12: 767. CrossRef
New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
Kan Chen, Yiyang Gao, Jing Li
European Journal of Medical Research.2023;[Epub] CrossRef
REVIEW OF SARS-CORONAVIRUS-2 REPERCUSSIONS ON THYROID GLAND IN THE CONTEXT OF HYPERTHYROIDISM
SHUBHAM SINGH, MONIKA, RUPA MAZUMDER, AVIJIT MAZUMDER
International Journal of Applied Pharmaceutics.2023; : 17. CrossRef
Effectiveness and potential mechanism of Jiawei-Xiaoyao-San for hyperthyroidism: a systematic review
Wenxin Ma, Xiaowen Zhang, Ruotong Zhao, Yang Tang, Xiaoyun Zhu, Longkun Liu, Mingyuan Xu, Ge Wang, Peiyue Peng, Jianping Liu, Zhaolan Liu
Frontiers in Endocrinology.2023;[Epub] CrossRef
Associations of serum keratin 1 with thyroid function and immunity in Graves’ disease
Chao-Wen Cheng, Wen-Fang Fang, Jiunn-Diann Lin, Appuwawadu Mestri Nipun Lakshitha de Silva
PLOS ONE.2023; 18(11): e0289345. CrossRef
Management of Graves’ hyperthyroidism: present and future
Luigi Bartalena, Eliana Piantanida, Daniela Gallo, Silvia Ippolito, Maria Laura Tanda
Expert Review of Endocrinology & Metabolism.2022; 17(2): 153. CrossRef
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
Journal of the Endocrine Society.2022;[Epub] CrossRef
Efficacy of Radioiodine Therapy in Patients With Primary Hyperthyroidism: An Institutional Review From Pakistan
Asim Munir Alvi, Umal Azmat, Waqas Shafiq, Abdul Hannan Ali Rasheed, Ahmed Imran Siddiqi, Sardar Khan, Sara Ashfaq, Hira Irfan , Humayun Bashir, Muhammad Abu Bakar, Kashif Asghar
Cureus.2022;[Epub] CrossRef
Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho
Endocrinology and Metabolism.2022; 37(3): 524. CrossRef
Endocrine Surgery and Pediatic Surgery Partnership Reduces Complication Rate of Pediatric Thyroidectomy
Ali Sayan, Mehmet Üstün, Mehmet Mert, Cem Karaali, Gökhan Köylüoğlu
Journal of Dr Behcet Uz Children s Hospital.2022; 12(2): 164. CrossRef
Thyroid-related adverse events induced by immune checkpoint inhibitors
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Frontiers in Endocrinology.2022;[Epub] CrossRef
A case of Hashimoto's thyroiditis following Graves' disease
Ibtissem Oueslati, Salma Salhi, Meriem Yazidi, Fatma Chaker, Melika Chihaoui
Clinical Case Reports.2022;[Epub] CrossRef
Changes in the T and B lymphocyte subset profiles upon treatment of patients with Graves’ disease with radioactive iodine
A. A. Savchenko, M. A. Dudina, S. A. Dogadin, A. G. Borisov, I. V. Kudryavtsev, D. V. Fomina, V. D. Belenyuk
Medical Immunology (Russia).2022; 24(5): 1007. CrossRef
A survey of the young person’s experience of Graves’ disease and its management
Laura Claire Lane, Judith Rankin, Tim Cheetham
Clinical Endocrinology.2021; 94(2): 330. CrossRef
Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Rajata Rajatanavin, Thep Himathongkam
Journal of the Endocrine Society.2021;[Epub] CrossRef
Dosimetry-guided radioiodine therapy of hyperthyroidism: long-term experience and implications for guidelines
Thomas Leitha, Manuela Schartel, Ingrid Hurtl, Rudolf Bednar, Franz König, Karl Mayrhofer, Flavia Pietschmann
Nuclear Medicine Communications.2021; 42(2): 150. CrossRef
Practice patterns and outcomes in the management of Thai patients with Graves’ disease
Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanathayanoroj, Nampetch Lekpittaya, Worawit Kittipoom, Tawee Anuntakulnatee, Somboon Vongterapak, Siriwan Butadej, Soontaree Nakas
Thyroid Research.2021;[Epub] CrossRef
Un case report letterario di tireotossicosi in La coscienza di Zeno di Italo Svevo
Francesco Trimarchi, Luigi Bartalena, Stefano Arieti, Roberto Toni
L'Endocrinologo.2021; 22(2): 149. CrossRef
Medical treatment of thyrotoxicosis
Lorenzo SCAPPATICCIO, Giuseppe BELLASTELLA, Maria I. MAIORINO, Luca GIOVANELLA, Katherine ESPOSITO
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2021;[Epub] CrossRef
Hiccups as a Rare Presentation of Thyrotoxicosis Triaged by an Epidural Steroid Injection
Omar Al-Radideh, Iyad Farouji, Theodore DaCosta, Hossam Abed, Nicholas Baranestky
Cureus.2021;[Epub] CrossRef
Long-term antithyroid drug therapy
David S. Cooper
Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 510. CrossRef
The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
Cancers.2021; 13(21): 5277. CrossRef
Recurrence of Graves’ Disease: What Genetics of HLA and PTPN22 Can Tell Us
Daniela Vejrazkova, Josef Vcelak, Eliska Vaclavikova, Marketa Vankova, Katerina Zajickova, Jana Vrbikova, Michaela Duskova, Petra Pacesova, Zdenek Novak, Bela Bendlova
Frontiers in Endocrinology.2021;[Epub] CrossRef
Most Patients with Graves’ Disease Treated with Antithyroid Drugs Eventually Require Additional Therapies
Mary H. Samuels
Clinical Thyroidology.2020; 32(1): 9. CrossRef
Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
Juan P. Brito, Stephanie Payne, Naykky Singh Ospina, Rene Rodriguez-Gutierrez, Spyridoula Maraka, Lindsey R. Sangaralingham, Nicole M. Iñiguez-Ariza, Victor M. Montori, Marius N. Stan
Thyroid.2020; 30(3): 357. CrossRef
Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience
Fereidoun Azizi
Thyroid.2020; 30(10): 1451. CrossRef
Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
Rui-Ting Hu, De-Shan Liu, Bin Li
BMC Endocrine Disorders.2020;[Epub] CrossRef
The Concept of Cure in Thyroid Diseases
Fereidoun Azizi
International Journal of Endocrinology and Metabolism.2020;[Epub] CrossRef
Der Biomarker TSH bei Schilddrüsenautonomien
K. Passek, N. Zulauf, E. Wanke, G. M. Oremek
Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie.2020; 70(4): 177. CrossRef
Management of Graves’ Hyperthyroidism: More Than a Century of Progression
Hengameh Abdi, Atieh Amouzegar
International Journal of Endocrinology and Metabolism.2020;[Epub] CrossRef
Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Fabrizio Lo Giudice, Francesco Frasca, Antonino Belfiore, Riccardo Vigneri
Frontiers in Endocrinology.2020;[Epub] CrossRef
Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review
Pei-Wen Wang
International Journal of Endocrinology and Metabolism.2020;[Epub] CrossRef
Radioiodine-131 therapy (RIT) in benign thyroid diseases: Personalized prescription based on objectives with optional use of pharmacological modulators
J. Clerc
Médecine Nucléaire.2020; 44(4): 250. CrossRef
Predicting the Risk of Graves Disease Relapse: Commentary on “Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease”
D. Gallo, M.L. Tanda, E. Piantanida
Endocrine Practice.2020; 26(9): 1039. CrossRef
Integrating Five Feature Types Extracted From Ultrasonograms to Improve the Prediction of Thyroid Papillary Carcinoma
Renxiang Zhu, Zhongyu Wang, Yifan Zhang, Bingxin Yu, Mingran Qi, Xin Feng, Chenjun Wu, Yuxuan Cui, Lan Huang, Fan Li, Fengfeng Zhou
IEEE Access.2019; 7: 101820. CrossRef
Serum TSH Receptor Antibodies Fall Gradually and Only Rarely Switch Functional Activity in Treated Graves’ Disease
Mary H. Samuels
Clinical Thyroidology.2019; 31(8): 330. CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease
Sandra M. McLachlan, Basil Rapoport
Endocrine.2019; 66(2): 137. CrossRef

Original Articles

Thyroid
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea: Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung; Endocrinol Metab. 2018;33(2):287-295. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.287

5,436 View
59 Download
31 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Background

Most patients with differentiated thyroid cancer (DTC) have a favorable prognosis. However, patients with DTC and initial distant metastasis have not been commonly found, and their clinical characteristics have seldom been reported. In this study, we analyzed the clinical features and prognosis of patients with DTC and initial distant metastasis in Korea.

Methods

We retrospectively reviewed the clinical data of 242 patients with DTC and initial distant metastasis treated from 1994 to 2013, collected from five tertiary hospitals in Korea.

Results

The patients' median age was 51 years, and 65% were women. They were followed for a median of 7 years. Lung was the most common site of distant metastasis: only lung 149 patients (62%), only bone 49 (20%), other single site one (pleura), and combined sites 43 (40 were lung and bone, two were bone and other site, and one was lung and other site). At the time of diagnosis, 50 patients (21%) had non-radioactive iodine (RAI) avidity. Five-year disease-specific survival (DSS) was 85% and 10-year DSS was 68%, which were better than those in previous studies. After multivariate analysis, old age, male sex, metastatic site, and histologic type (follicular type) were significant factors for poor prognosis. However, negative RAI avidity status was not a significant prognostic factor after adjusting for other variables.

Conclusion

The prognosis of Korean patients with DTC and initial distant metastasis was better than in previous studies. Old age, male sex, metastasis site, and histologic type were significant prognostic factors.

Citations

Citations to this article as recorded by

Case report: A case of hyperthyroidism secondary to bone metastasis of differentiated thyroid cancer
Tingyu Gu, Zhihong Zhao, Yuanyuan Shi, Zhenhua Sun, Yao Wang, Zhiyuan He, Kun Wang
Frontiers in Oncology.2024;[Epub] CrossRef
Theranostics of Thyroid Cancer
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
Seminars in Nuclear Medicine.2024;[Epub] CrossRef
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
Cancers.2023; 15(9): 2510. CrossRef
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
Petra Petranović Ovčariček, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Cancers.2023; 15(17): 4290. CrossRef
Differentiating pulmonary metastasis from benign lung nodules in thyroid cancer patients using dual-energy CT parameters
Taeho Ha, Wooil Kim, Jaehyung Cha, Young Hen Lee, Hyung Suk Seo, So Young Park, Nan Hee Kim, Sung Ho Hwang, Hwan Seok Yong, Yu-Whan Oh, Eun-Young Kang, Cherry Kim
European Radiology.2022; 32(3): 1902. CrossRef
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
Hsi-Chen Tsai, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, Miaw-Jene Liou
Diagnostics.2022; 12(1): 221. CrossRef
Long-Term Quality of Life (5-15 Years Post-Thyroidectomy) of Thyroid Carcinoma Patients in Two Tertiary Care Hospitals
Mohammed Yousef Alyousef, Mohammed Khaled Ghandour, Mohammed Al-Mohawes, Mosaad Alnwaisir, Tahera Islam, Khalid Al Qahtani
Cureus.2022;[Epub] CrossRef
Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition
Pınar Celepli, İrem Bigat, Sefika Karabulut, Salih Celepli, Sema Hücümenoğlu
Annals of Diagnostic Pathology.2022; 59: 151973. CrossRef
Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria
Yu Liang, Xingxiang Huang, Zhe Song, Yang Yang, Ju Lei, Mei Ren, Li Tan, Hui Zhang, Francis Moore
PLOS ONE.2022; 17(6): e0269994. CrossRef
Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report
Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli
World Journal of Obstetrics and Gynecology.2022; 11(3): 33. CrossRef
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Juan Antonio Vallejo Casas, Marcel Sambo, Carlos López López, Manuel Durán-Poveda, Julio Rodríguez-Villanueva García, Rita Joana Santos, Marta Llanos, Elena Navarro-González, Javier Aller, Virginia Pubul, Sonsoles Guadalix, Guillermo Crespo, Cintia Gonzál
European Thyroid Journal.2022;[Epub] CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
Evert F S van Velsen, Merel T Stegenga, Folkert J van Kemenade, Boen L R Kam, Tessa M van Ginhoven, W Edward Visser, Robin P Peeters
The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e457. CrossRef
Usefulness of a 3D‐Printed Thyroid Cancer Phantom for Clinician to Patient Communication
Dayeong Hong, Sangwook Lee, Taehun Kim, Jung Hwan Baek, Won Woong Kim, Ki‐Wook Chung, Namkug Kim, Tae‐Yon Sung
World Journal of Surgery.2020; 44(3): 788. CrossRef
Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2020; 30(3): 418. CrossRef
Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
Endocrine.2020; 70(2): 280. CrossRef
Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
PLOS ONE.2020; 15(8): e0238207. CrossRef
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Thyroid.2019; 29(12): 1804. CrossRef
Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
Xin-Yun Zhang, Jian-Wen Sun, Zhong-Ling Qiu, Yang Wang, Xiao-Yue Chen, Jin-Hua Zhao, Quan-Yong Luo
Endocrine.2019; 66(2): 254. CrossRef
Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis
Nilma Malik, Alyaksandr V. Nikitski, Elie Klam, Jason Hunt, Benjamin Witt, Barbara Chadwick, Yuri E. Nikiforov, Devaprabu Abraham
Endocrine Practice.2019; 25(12): 1255. CrossRef
Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Scientific Reports.2019;[Epub] CrossRef
Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano
Endocrine.2019; 65(3): 630. CrossRef
The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study
Young Ki Lee, Daham Kim, Dong Yeob Shin, Cho Rok Lee, Eun Jig Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Annals of Surgical Oncology.2019; 26(7): 2200. CrossRef
Risk Factors for Distant Metastasis in Follicular Thyroid Carcinoma in Korea
Shin Dol Jo, Joon-Hyop Lee, Suk Ha Kang, Yun Yeong Kim, Yong Soon Chun, Heung Kyu Park, Sang Tae Choi, Jin Mo Kang, Yoo Seung Chung
Journal of Endocrine Surgery.2019; 19(1): 1. CrossRef
Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis
Houwei Zhu, Yanqing Qu
Oncology Letters.2019;[Epub] CrossRef
甲状腺腫瘍治療の最新情報

Nippon Jibiinkoka Gakkai Kaiho.2018; 121(11): 1336. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef

Thyroid
Star-Shaped Intense Uptake of ¹³¹I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq: Sung Hye Kong, Jung Ah Lim, Young Shin Song, Shinje Moon, Ye An Kim, Min Joo Kim, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park; Endocrinol Metab. 2018;33(2):228-235. Published online May 4, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.228

5,300 View
50 Download
3 Web of Science
3 Crossref

Abstract PDF PubReader ePub

Background

After initial radioactive iodine (RAI) treatment in differentiated thyroid cancer patients, we sometimes observe a star-shaped region of intense uptake of ¹³¹I on whole body scans (WBSs), called a ‘star artifact.’ We evaluated the clinical implications of star artifacts on the success rate of remnant ablation and long-term prognosis.

Methods

Total 636 patients who received ¹³¹I dose of 1.1 GBq for the initial RAI therapy and who did not show distant metastasis at the time of diagnosis were retrospectively evaluated. A negative second WBS was used for evaluating the ablation efficacy of the RAI therapy. Among them, 235 patients (36.9%) showed a star artifact on their first WBS.

Results

In patients with first stimulated thyroglobulin (sTg) levels ≤2 ng/mL, patients with star artifacts had a higher rate of negative second WBS compared with those without star artifacts (77.8% vs. 63.9%, P=0.044), and showed significantly higher recurrence-free survival (P=0.043) during the median 8.0 years (range, 1.0 to 10.0) of follow-up. The 5- and 10-year recurrence rates (5YRR, 10YRR) were also significantly lower in patients with star artifacts compared with those without (0% vs. 4.9%, respectively, P=0.006 for 5YRR; 0% vs. 6.4%, respectively, P=0.005 for 10YRR). However, ablation success rate or recurrence-free survival was not different among patients whose first sTg levels >2 ng/mL regardless of star artifacts.

Conclusion

Therefore, star artifacts at initial RAI therapy imply a good ablation efficacy or a favorable long-term prognosis in patients with sTg levels ≤2 ng/mL.

Citations

Citations to this article as recorded by

Prognostic value of star-shaped intense uptake of 131I in thyroid cancer patients
Liu Xiao, Wen Jie Zhang, Yue Qi Wang, Lin Li
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2021; 40(1): 30. CrossRef
Valores pronósticos de la captación en estrella de 131I en pacientes con cáncer diferenciado de tiroides
L. Xiao, W.J. Zhang, Y.Q. Wang, L. Li
Revista Española de Medicina Nuclear e Imagen Molecular.2021; 40(1): 30. CrossRef
Comparison between planar and single-photon computed tomography images for radiation intensity quantification in iodine-131 scintigraphy
Yusuke Iizuka, Tomohiro Katagiri, Minoru Inoue, Kiyonao Nakamura, Takashi Mizowaki
Scientific Reports.2021;[Epub] CrossRef

Clinical Study
Prevalence of Hyponatremia in Hypothyroid Patients during Radioactive ¹³¹I Ablation for Differentiated Thyroid Cancer: Single Institution Experience: Juan Carlo P. Dayrit, Elaine C. Cunanan, Sjoberg A. Kho; Endocrinol Metab. 2016;31(3):410-415. Published online August 17, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.3.410

3,446 View
34 Download
3 Web of Science
2 Crossref

Abstract PDF PubReader

Background

Hyponatremia developing in hypothyroid patients has been encountered in clinical practice; however, its prevalence has not been well established.

Methods

Thirty patients diagnosed with differentiated thyroid cancer, rendered hypothyroid after surgery and levothyroxine withdrawal, and who are for radioactive iodine (RAI) ablation were included. Serum sodium concentrations were measured twice, at the time of admission for RAI ablation, and before discharge after increased oral fluid intake. The outcome measures were to determine the prevalence of hyponatremia among hypothyroid patients prior to RAI ablation and after oral hydration post-RAI, and to correlate the serum sodium levels pre-RAI and post-RAI with thyroid-stimulating hormone (TSH) concentration and age.

Results

Thirty patients were included, with ages from 23 to 65 years old (median, 40). Two patients (6.7%) were hyponatremic prior to RAI ablation, and eight patients (26.7%) had mild hyponatremia (130 to 134 mEq/L) after RAI and hydration. There was no significant correlation between TSH levels and serum sodium levels prior to or after RAI. There was also no significant correlation between pre- and post-RAI sodium concentration and age.

Conclusions

The prevalence of hyponatremia pre-RAI was 6.7%, and 26.7% post-RAI. No significant correlation was noted between TSH concentration and age on pre- or post-RAI sodium concentrations. Routine measurement of serum sodium post-RAI/isolation is still not advised. Measurement of sodium post-RAI may be considered in patients who are elderly, with comorbid conditions or on medications.

Citations

Citations to this article as recorded by

Is there a causal relationship between hypothyroidism and hyponatremia?
Julie Chen
Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub] CrossRef
Endocrinopathy-induced euvolemic hyponatremia
Talia Diker-Cohen, Benaya Rozen-Zvi, Dana Yelin, Amit Akirov, Eyal Robenshtok, Anat Gafter-Gvili, Daniel Shepshelovich
Internal and Emergency Medicine.2018; 13(5): 679. CrossRef

Clinical Study
Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults: Abigail U. Canto, Paulette N. Dominguez, Cecilia A. Jimeno, Jerry M. Obaldo, Ruben V. Ogbac; Endocrinol Metab. 2016;31(1):168-173. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.168

4,493 View
52 Download
11 Web of Science
11 Crossref

Abstract PDF PubReader

Background

Radioactive iodine as a treatment modality has been shown in several studies to be a safe and effective therapy for Graves disease. However, there is still no uniformity regarding optimal dosing method. The aim of this study is to compare the efficacy of calculated and fixed dosing of radioiodine for the treatment of Graves disease.

Methods

A hundred twenty-two patients diagnosed with Graves disease were randomized to receive either fixed or calculated dose of radioiodine. Those randomized to fixed activity received either low fixed activity at 9.9 mCi for thyroid gland size <40 g or high fixed activity at 14.9 mCi for thyroid gland size 40 to 80 g, and those grouped to calculated activity received 160 µCi/g of thyroid tissue adjusted for 24 hours radioiodine uptake. Thyroid function tests (free thyroxine [T4] and thyroid stimulating hormone [TSH]) were monitored at 10, 16, and 24 weeks after radioactive iodine therapy. The primary outcome, treatment failure was defined as persistently elevated free T4 and low TSH.

Results

Of the 122 patients randomized, 56 in the fixed dose group and 56 in the calculated dose group completed the follow-up. At the end of 6 months, the percentage of treatment failure was 37.50% in the calculated dose group versus 19.64% in the fixed dose group with a relative risk of 0.53 (95% confidence interval, 0.28 to 0.98) favoring the fixed dose group.

Conclusion

Fixed dose radioiodine has a significantly lower incidence of persistent hyperthyroidism at 6 months post-radioactive therapy.

Citations

Citations to this article as recorded by

The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
Felix Quataert, Bert Bravenboer, Marleen Keyaerts, Corina Emilia Andreescu
Hormone and Metabolic Research.2024; 56(02): 134. CrossRef
Possibility analysis of thyroid imaging parameters for dose adjustment in 131I treatment of hyperthyroidism
Xiaonan ZHANG, Junhong LI, Hui ZHOU, Qiteng LU, Hailian WEI, Aifeng LI, Xinyu WEI, Zhixiao WEI
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub] CrossRef
Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience
Busra Kuyumcu Demir, Ersen Karakilic, Emre Sedar Saygili, Nilgun Araci, Semra Ozdemir
Endocrine Practice.2022; 28(8): 749. CrossRef
Changes in Radiosensitivity to Gamma-Rays of Lymphocytes from Hyperthyroid Patients Treated with I-131
Valentina Dini, Massimo Salvatori, Mauro Belli, Maria Elena Lago, Alessandra Nosdeo, Donatella Pia Dambra, Luisa Lo Conte, Ilaria Pecchia, Alessandro Giordano
International Journal of Molecular Sciences.2022; 23(17): 10156. CrossRef
Current controversies in the management of Graves’ hyperthyroidism
Niroshan Francis, Thanuya Francis, John H Lazarus, Onyebuchi E Okosieme
Expert Review of Endocrinology & Metabolism.2020; 15(3): 159. CrossRef
Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves’ Ophthalmopathy
Shahrara Ariamanesh, Narjess Ayati, Zahra Mazloum Khorasani, Zohreh Mousavi, Victoria Kiavash, Zahra Kiamanesh, Seyed Rasoul Zakavi
Clinical Nuclear Medicine.2020; 45(7): 514. CrossRef
The relationship between thyroid eye disease and radioiodine treatment
Sarameth Thou, Sobhan Vinjamuri
Nuclear Medicine Communications.2019; 40(3): 194. CrossRef
99mTc-pertechnetate thyroid scintigraphy predicts clinical outcomes in personalized radioiodine treatment for Graves’ disease
Zhao Lina, Zhang Wenqi, Xin Yubo, Wen Qiang, Bail Lin, Guan Feng, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2018; 37(6): 349. CrossRef
Predicción de los resultados clínicos en el tratamiento personalizado con yodo radiactivo de la enfermedad de Graves, mediante gammagrafía tiroidea con 99mTc-pertecnetato
L. Zhao, W. Zhang, Y. Xin, Q. Wen, L. Bail, F. Guan, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular.2018; 37(6): 349. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders
Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
Nuclear Medicine Communications.2017; 38(9): 756. CrossRef

Review Article

Thyroid
Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea: Jae Hoon Chung; Endocrinol Metab. 2013;28(3):157-163. Published online September 13, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.3.157

3,715 View
39 Download
19 Crossref

Abstract PDF PubReader

Preparation for radioactive iodine (RAI) therapy includes an increased serum thyroid stimulating hormone level and a low iodine diet (LID). Because of extremely high iodine intake, some physicians have advocated a more stringent LID for greater than 2 weeks in Korean patients with thyroid cancer prior to RAI therapy; however, it is very difficult to maintain a stringent LID for a longer period of time. According to recent reports in Korea, a nonstringent, simple LID for only 1 week might be enough prior to RAI therapy, if the patients can be educated intensively by specially trained staff. The measurement of simple urinary iodine concentration (UIC; µg/L) may underestimate daily iodine excretion in patients with a urinary volume of more than 1 L/day and can also be affected by dilution status. Simple UIC had a weaker correlation than the iodine/creatinine (I/Cr) ratio. Therefore, the urinary I/Cr ratio can replace 24-hour urine iodine excretion instead of simple UIC, although it may overestimate iodine intake in patients with malnutrition or poor muscle mass. The measurement of serum iodine level might be useful as an adjunct parameter for assessing LID preparation, but its sensitivity and specificity were relatively low compared to the urinary I/Cr ratio.

Citations

Citations to this article as recorded by

Theranostics of Thyroid Cancer
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
Seminars in Nuclear Medicine.2024;[Epub] CrossRef
Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
Clinical Oncology.2023; 35(1): 42. CrossRef
Nomogram Model Based on Iodine Nutrition and Clinical Characteristics of Papillary Thyroid Carcinoma to Predict Lateral Lymph Node Metastasis
Junrong Wang, Yuzhang Gao, Yuxuan Zong, Weitong Gao, Xueying Wang, Ji Sun, Susheng Miao
Cancer Control.2023;[Epub] CrossRef
Is a 4-Day Low-Iodine Diet Sufficient for Radioactive Iodine Ablation in Differentiated Thyroid Cancer Treatment?
Alex Tessnow
Clinical Thyroidology.2022; 34(3): 123. CrossRef
The Role of the Nurse in Patients on Low Iodine Diet Period
Nedıme KOSGEROGLU, Dilek GÜMÜŞ, Handan KOYUNCU
OSMANGAZİ JOURNAL OF MEDICINE.2022;[Epub] CrossRef
The Interplay Between Thyroid Dysfunction and Kidney Disease
Yoko Narasaki, Peter Sohn, Connie M. Rhee
Seminars in Nephrology.2021; 41(2): 133. CrossRef
Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer
Yuyan Jiang, Jiahui Jin, Jingzheng Fan, Chao Huang, Qiang Jia, Jian Tan, Xianghui He, Xiangqian Zheng, Yue Zhao, Qing Zhang, Zhaowei Meng, Yan Wang
Biomarkers in Medicine.2021; 15(11): 879. CrossRef
Update on Thyroid Hormone Levels and Thyroid Dysfunction in the Korean Population Based on Data from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
Jae Hoon Chung
Endocrinology and Metabolism.2020; 35(1): 7. CrossRef
Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer
Malik E. Juweid, Mark Tulchinsky, Ayman Mismar, Munther Momani, Ayman A. Zayed, Hussam Al Hawari, Nader Albsoul, Felix M. Mottaghy
International Journal of Cancer.2020; 147(9): 2345. CrossRef
Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
Endocrine.2020; 70(2): 280. CrossRef
Urinary iodine concentration and thyroid hormones: Korea National Health and Nutrition Examination Survey 2013–2015
Hye In Kim, Hyun-Kyung Oh, So Young Park, Hye Won Jang, Myung-Hee Shin, Sun Wook Kim, Tae Hyuk Kim, Jae Hoon Chung
European Journal of Nutrition.2019; 58(1): 233. CrossRef
Analysis of Iodine Content in Salts and Korean Sauces for Low-Iodine Diet Education in Korean Patients with Thyroid Cancer Preparing for Radioiodine Therapy
Soo Young Kim, Jung Mi Park, Jae Pil Hwang
Nuclear Medicine and Molecular Imaging.2018; 52(3): 229. CrossRef
Evaluation of Thyroid Hormone Levels and Urinary Iodine Concentrations in Koreans Based on the Data from Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
Jae Hoon Chung
Endocrinology and Metabolism.2018; 33(2): 160. CrossRef
The application of serum iodine in assessing individual iodine status
Xing Jin, Peng Jiang, Lixiang Liu, Qingzhen Jia, Peng Liu, Fangang Meng, Xiaoye Zhang, Yunfeng Guan, Yi Pang, Zheng Lu, Hongmei Shen
Clinical Endocrinology.2017; 87(6): 807. CrossRef
Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region
Dal Lae Ju, Young Joo Park, Hee-Young Paik, Min-Ji Kim, Seonyeong Park, Kyong Yeun Jung, Tae Hyuk Kim, Hun Sung Choi, Yoon Ju Song
Nutrition Research and Practice.2016; 10(2): 167. CrossRef
Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy
Kyem Ju Lee, Sung Ok Chang, Kwang Yoon Jung
European Journal of Oncology Nursing.2016; 23: 43. CrossRef
The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy
Dal Lae Ju, Young Joo Park, Hee-Young Paik, YoonJu Song
Clinical Nutrition Research.2015; 4(4): 267. CrossRef
Effect of Iodine Restriction on Thyroid Function in Subclinical Hypothyroid Patients in an Iodine-Replete Area: A Long Period Observation in a Large-Scale Cohort
Ji Young Joung, Yoon Young Cho, Sun-Mi Park, Tae Hun Kim, Na Kyung Kim, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung
Thyroid.2014; 24(9): 1361. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

Case Report

Thyroid
Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease: Sun Hwa Kim, Hee Young Kim, Kwang Yoon Jung, Dong Seop Choi, Sin Gon Kim; Endocrinol Metab. 2013;28(1):61-64. Published online March 25, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.1.61

3,965 View
30 Download
3 Crossref

Abstract PDF PubReader

Radioactive iodine (RAI) therapy has been used as a treatment option for Graves' disease, and it has been widely accepted to be safe. On the other hand, some evidence suggests that RAI therapy is possibly associated with a small increased risk of thyroid cancer. Herein, we report a rare case of anaplastic thyroid carcinoma (ATC) associated with Graves' disease, following RAI treatment. A 42-year-old woman had been diagnosed with Graves' disease and although she was treated with an antithyroid drug, she remained in a hyperthyroid state, which led to two RAI treatments. More than 10 years later, the patient revisited our clinic due to hoarseness, dysphagia, and dyspnea, which had lasted for 2 months. Neck computed tomography suggested thyroid carcinoma and a lymph node biopsy showed metastatic papillary carcinoma. The patient underwent total thyroidectomy and was finally diagnosed as having an ATC. It is not clear if the occurrence of ATC reported here was influenced by the RAI therapy or alternatively, it may only represent the delayed recognition of a rare change in the natural history of Graves' disease. Nevertheless, this report is worthwhile since it presents a very rare case of ATC that occurred eleven years after the RAI therapy for Graves' disease.

Citations

Citations to this article as recorded by

Evaluation of ultrasonographical and cytological features of thyroid nodules in patients treated with radioactive iodine for hyperthyroidism
Muhammet C. Bilginer, Didem Ozdemir, Fatma N. C. Seyrek, Nilufer Yildirim, Aylin K. Yazgan, Mehmet Kilic, Reyhan Ersoy, Bekir Cakir
Diagnostic Cytopathology.2020; 48(1): 3. CrossRef
Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves’ disease by radioactive iodine
O Hamdy, S Raafat, GA Saleh, K Atallah, Mahmoud M Saleh, AM Shebl, MA Hegazy
The Annals of The Royal College of Surgeons of England.2019; 101(5): e122. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

Original Article

Therapeutic Response to Radioactive Iodine Treatment in Graves' Disease.: Hye Young Park, Hee Sang Kong, Yon Sil Jung, Sung Kwang Lee, Hong Kyu Kim, Moon Ho Kang; J Korean Endocr Soc. 1999;14(4):679-687. Published online January 1, 2001

1,047 View
19 Download

Abstract PDF: BACKGROUND
Prediction of therapeutic response to radioactive iodine (RAI) in Graves disease is poorly understood. Although thyrotropin binding inhibitor immunoglobulin (TBII) level is a strong index for relapse after antithyroid drug treatment, conflicting results are described regarding its prognostic significance in Graves disease treated with RAI. This study is to evaluate possible prognostic factors including TBII wbich affect the outcome of RAI therapy in Graves disease. METHODS: Two hundred and one patients with Graves disease who were followed for over 12 months after RAI treatment were studied retrospectively. The subjects were divided into hypothyroid, euthyroid and hyperthyroid groups, based on the thyroid function evaluated at 12 months after RAI therapy. We evaluated the association of clinical parameters including patients age, goiter size, degree of hyperthyroidism and TBII index with outcome of RAI treatment. RESULTS: In Graves disease, response rate to RAI was 70.1% (hypothyroid 22.4% and euthyroid 47.7%) until 12th month. The mean age of hypothyroid group was 40+/-11 years, significantly older than that other groups (euthyroid: 33+/-12, hyperthyroid: 35+/-13, p<0.05). Initial level of thyroid function, duration of antithyroid drug treatment prior to RAI, goiter size and dosage of RAI were not significantly different between the groups. There were 61 patients who had both TBII tests before and after RAI. Twelve had negative TBII and 49 had positive TBII before RAI admini-stration. The rate of unremitted hyperthyroidism after RAI therapy was significantly lower in patients with negative TBII than in those with positive TBII prior to RAI treatment( 0% versus 46.9%, p<0.05). CONCLUSION: Graves patients with positive TBII prior to RAI therapy were associated with lower therapeutic response to RAI than those with negatve TBII. And old age was associated with the development of early hypothyroidism after RAI therapy. These results suggest these factors be also considered in the treatment of Graves disease with RAI.

First
Prev
Page of 1
Next
Last

Search